OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts

OnKure Therapeutics, Inc.

Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.
Cash and equivalents $59.1M as of Dec 31, 2025.
PIKture-01 trial (OKI-219) data expected March 2026 across mono, combo, and triplet arms.
Next-gen PI3Kα pan-mutant inhibitor candidate for HR+ breast cancer to be announced March 2026.
R&D expenses $10.7M vs $14.4M YoY; G&A $3.4M vs $4.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.